159 related articles for article (PubMed ID: 34584583)
61. How to use faecal calprotectin in management of paediatric inflammatory bowel disease.
Saha A; Tighe MP; Batra A
Arch Dis Child Educ Pract Ed; 2016 Jun; 101(3):124-8. PubMed ID: 26848103
[TBL] [Abstract][Full Text] [Related]
62. Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease.
Amcoff K; Cao Y; Zhulina Y; Lampinen M; Halfvarson J; Carlson M
Scand J Gastroenterol; 2019 Oct; 54(10):1237-1244. PubMed ID: 31577465
[No Abstract] [Full Text] [Related]
63. Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative Study.
Zollner A; Schmiderer A; Reider SJ; Oberhuber G; Pfister A; Texler B; Watschinger C; Koch R; Effenberger M; Raine T; Tilg H; Moschen AR
J Crohns Colitis; 2021 Jan; 15(1):43-54. PubMed ID: 32556317
[TBL] [Abstract][Full Text] [Related]
64. Faecal calprotectin: a marker of inflammation throughout the intestinal tract.
Summerton CB; Longlands MG; Wiener K; Shreeve DR
Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):841-5. PubMed ID: 12172403
[TBL] [Abstract][Full Text] [Related]
65. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
[TBL] [Abstract][Full Text] [Related]
66. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.
Diederen K; Hoekman DR; Leek A; Wolters VM; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Benninga MA; Kindermann A
Aliment Pharmacol Ther; 2017 Apr; 45(7):951-960. PubMed ID: 28138990
[TBL] [Abstract][Full Text] [Related]
67. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases.
Buisson A; Mak WY; Andersen MJ; Lei D; Kahn SA; Pekow J; Cohen RD; Zmeter N; Pereira B; Rubin DT
J Crohns Colitis; 2019 Aug; 13(8):1012-1024. PubMed ID: 30726887
[TBL] [Abstract][Full Text] [Related]
68. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice.
Reenaers C; Bossuyt P; Hindryckx P; Vanpoucke H; Cremer A; Baert F
United European Gastroenterol J; 2018 Oct; 6(8):1117-1125. PubMed ID: 30288273
[TBL] [Abstract][Full Text] [Related]
69. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease.
Bunn SK; Bisset WM; Main MJ; Gray ES; Olson S; Golden BE
J Pediatr Gastroenterol Nutr; 2001 Jul; 33(1):14-22. PubMed ID: 11479402
[TBL] [Abstract][Full Text] [Related]
70. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
Klingberg E; Strid H; Ståhl A; Deminger A; Carlsten H; Öhman L; Forsblad-d'Elia H
Arthritis Res Ther; 2017 Feb; 19(1):21. PubMed ID: 28148281
[TBL] [Abstract][Full Text] [Related]
71. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease.
Ashorn S; Honkanen T; Kolho KL; Ashorn M; Välineva T; Wei B; Braun J; Rantala I; Luukkaala T; Iltanen S
Inflamm Bowel Dis; 2009 Feb; 15(2):199-205. PubMed ID: 18618670
[TBL] [Abstract][Full Text] [Related]
72. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure.
Kristensen V; Malmstrøm GH; Skar V; Røseth A; Moum B
Scand J Gastroenterol; 2016; 51(5):548-55. PubMed ID: 26634305
[TBL] [Abstract][Full Text] [Related]
73. Clinical usefulness of the faecal calprotectin test in suspected paediatric inflammatory bowel disease.
Akobeng AK
Acta Paediatr; 2018 Nov; 107(11):2019-2023. PubMed ID: 29706011
[TBL] [Abstract][Full Text] [Related]
74. Faecal calprotectin concentrations in gastrointestinal diseases.
Wang S; Wang Z; Shi H; Heng L; Juan W; Yuan B; Wu X; Wang F
J Int Med Res; 2013 Aug; 41(4):1357-61. PubMed ID: 23723365
[TBL] [Abstract][Full Text] [Related]
75. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
[TBL] [Abstract][Full Text] [Related]
76. Calprotectin as a diagnostic tool for inflammatory bowel diseases.
Chatzikonstantinou M; Konstantopoulos P; Stergiopoulos S; Kontzoglou K; Verikokos C; Perrea D; Dimitroulis D
Biomed Rep; 2016 Oct; 5(4):403-407. PubMed ID: 27699005
[TBL] [Abstract][Full Text] [Related]
77. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease.
Quail MA; Russell RK; Van Limbergen JE; Rogers P; Drummond HE; Wilson DC; Gillett PM
Inflamm Bowel Dis; 2009 May; 15(5):756-9. PubMed ID: 19107785
[TBL] [Abstract][Full Text] [Related]
78. Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study.
Walker GJ; Moore L; Heerasing N; Hendy P; Perry MH; McDonald TJ; Debenham T; Bethune R; Bewshea C; Hyde C; Heap GA; Singh A; Calvert C; Kennedy NA; Goodhand JR; Ahmad T
Aliment Pharmacol Ther; 2018 Apr; 47(8):1103-1116. PubMed ID: 29508423
[TBL] [Abstract][Full Text] [Related]
79. Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time.
Amcoff K; Stridsberg M; Lampinen M; Magnuson A; Carlson M; Halfvarson J
Scand J Gastroenterol; 2017 Mar; 52(3):344-350. PubMed ID: 27881032
[TBL] [Abstract][Full Text] [Related]
80. eHealth: Disease activity measures are related to the faecal gut microbiota in adult patients with ulcerative colitis.
Ankersen DV; Weimers P; Marker D; Johannesen T; Iversen S; Lilje B; Kristoffersen AB; Saboori S; Paridaens K; Skytt Andersen P; Burisch J; Munkholm P
Scand J Gastroenterol; 2020 Nov; 55(11):1291-1300. PubMed ID: 33045169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
